ClinicalTrials.gg
TerminatedNCT04191096Updated Sep 28, 2026Results posted

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

A Phase 3 interventional study of Pembrolizumab and Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer, sponsored by Merck Sharp & Dohme LLC. Terminated at 234 sites in 29 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study stopped due to futility
Updated Sep 28, 2026Now TerminatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,251
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and 2) overall survival (OS). As of 19-JAN-2023, the study was unblinded and all study participants stopped ongoing treatment with pembrolizumab/placebo and will continue to receive Standard of Care treatment until meeting protocol-specified discontinuation criteria if deriving clinical benefit. Safety analysis will be performed at the end of the study; there will be no further analyses for efficacy and electronic patient-reported outcome (ePRO) endpoints collected from participants beyond the IA1 cutoff date. All study participants will stop ongoing treatment with pembrolizumab/placebo. Exceptions may be requested for study participants who, in the assessment of their study physician, are benefitting from the combination of enzalutamide and pembrolizumab, after consulting with the Sponsor. All other study participants should be discontinued from study and be offered standard of care (SOC) treatment as deemed necessary by the Investigator. If enzalutamide as SOC is not accessible off study to the participant, central sourcing may continue. As of Amendment 04, disease progression will no longer be centrally verified, participants will only be assessed locally. As of Amendment 4, Second Course treatment is not an option for participants. There are currently no participants in the Second Course Phase.

02

Conditions studied

  • Metastatic Hormone-Sensitive Prostate Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1),
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants with - or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has disease assessed by investigator and verified by BICR by either ≥2 bone lesions on bone scan and/or visceral disease by computed tomography/magnetic resonance imaging (CT/MRI)
  • Willing to maintain continuous Androgen Deprivation Therapy (ADT) with a luteinizing-hormone releasing hormone (LHRH) agonists or antagonists during study treatment or have a history of bilateral orchiectomy
  • Has an (ECOG) performance status of 0 or 1 assessed within 10 days of randomization
  • Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization
  • Has adequate organ function
  • Has provided newly obtained core or excisional (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample
  • Male participants must agree to the following during the intervention period and for at least 120 days after the last dose of study intervention: Refrain from donating sperm PLUS either be abstinent from heterosexual intercourse and agree to remain abstinent OR agree to use , unless confirmed to be azoospermic
  • Male participants must agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person of any sex

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment in the last 3 years
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy
  • Has undergone major surgery including local prostate intervention (excluding prostate ) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications
  • Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules
  • Has an active infection (including tuberculosis) requiring systemic therapy
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has known active (HIV), virus (HBV) or virus (HCV) infection
  • Has known or suspected central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of seizure or any condition that may predispose to seizure
  • Has a history of loss of consciousness within 12 months of screening
  • Has had myocardial infarction or uncontrolled angina within 6 months prior to randomization, or has class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure
  • Has hypotension (systolic blood pressure \<86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit
  • Has a history of ventricular arrhythmias
  • Has to pembrolizumab and/or enzalutamide and/or any of their
  • Has received prior ADT as /adjuvant therapy for non-metastatic prostate cancer for >39 months in duration or within 9 months prior to randomization or with evidence of disease progression while receiving ADT
  • Has had prior treatment with a next generation hormonal agent (eg, abiraterone, enzalutamide, apalutamide, darolutamide)
  • Has received prior therapy with an anti-programmed cell death-1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received a within 30 days prior to randomization
  • Has a "superscan" bone scan
  • Has had an allogenic tissue/solid organ transplant
  • Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
  • Has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer with the following exceptions:

    1. Up to 3 months of ADT or orchiectomy with or without concurrent first-generation antiandrogens, if patient was not treated with docetaxel
    2. May have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to randomization
    3. For participants with low volume metastatic disease, may have 1 course of definitive radiotherapy if it was administered at least 4 weeks prior to randomization
    4. Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of randomization and no evidence of disease progression. In these participants up to 6 months of ADT permitted
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,251 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Enzalutamide + ADT

    Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.

    Biological: Pembrolizumab · Drug: Enzalutamide · Drug: Androgen Deprivation Therapy (ADT)

  • Placebo comparator
    Placebo + Enzalutamide + ADT

    Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.

    Drug: Enzalutamide · Drug: Androgen Deprivation Therapy (ADT) · Other: Placebo

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.

    Also known as: KEYTRUDA®, MK-3475

  • Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

    Also known as: XTANDI®

  • DrugAndrogen Deprivation Therapy (ADT)

    Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.

  • OtherPlacebo

    Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    rPFS was defined as the time from randomization to occurrence of: radiological tumor progression using RECIST 1.1 as assessed by BICR; progression of bone lesions using PCWG criteria; or death due to any cause. Progression as per modified RECIST 1.1 was ≥20% increase in sum of diameters of target lesions and progression of existing non-target lesions. Progression of bone lesions by PCWG criteria was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and was persistent for ≥6 weeks. The rPFS was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without a rPFS event were censored at the date of last disease assessment.

    Time frame: Up to approximately 32 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without documented death at the time of the analysis were censored at the date of the last follow-up.

    Time frame: Up to approximately 32 months

Secondary outcomes

  1. Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)

    TFST was defined as the time from randomization to initiation of the first subsequent anti-cancer therapy or death; whichever occurred first. The TFST was calculated using the product limit (Kaplan-Meier) method for censored data. Participants without documented event at time of analysis will be censored at the date of last known time to have not received subsequent new anti-cancer therapy.

    Time frame: Up to Approximately 32 months

  2. Time to First Symptomatic Skeletal-related Event (TTSSRE)

    TTSSRE was the time from randomization to the first symptomatic skeletal-related event defined as: use of external-beam radiation therapy (EBRT) to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathologic bone fracture (vertebral or nonvertebral), occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention, whichever occurs first. The TTSSRE was calculated using the Kaplan-Meier method for censored data. Participants without symptomatic skeletal-related events were censored at the last evaluable assessment.

    Time frame: Up to Approximately 32 months

  3. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was the time from randomization to PSA progression. The PSA progression date was defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. Time to PSA was calculated using Kaplan-Meier method for censored data. Participants without PSA progression were censored at the last PSA date.

    Time frame: Up to Approximately 32 months

  4. Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of PCWG-Modified RECIST 1.1 as Assessed by BICR

    The time to radiographic soft tissue progression was defined as the time from randomization to radiographic soft tissue progression per soft tissue rules of PCWG-modified RECIST 1.1 as assessed by BICR. Progression was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered progression. Time to radiographic soft tissue progression was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without radiographic soft tissue progression were censored at the last evaluable assessment.

    Time frame: Up to Approximately 32 months

  5. Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item #3 ("Worst Pain in 24 Hours") and Opiate Use

    TTPP was defined as the time from randomization to pain progression as determined by Item 3 of the BPI-SF. Pain progression was defined as: 1) For participants asymptomatic at baseline: a \>2-point change from baseline in the average BPI-SF item 3 score at 2 consecutive visits or initiation of opioid use for pain 2) For participants symptomatic at baseline (average BPI-SF Item 3 score \>0 and/or currently taking opioids; a \>2-point change from baseline in the average BPI-SF Item 3 score and the average worst pain score \>4 and no decrease in average opioid use. TTPP was calculated using the Kaplan-Meier method for censored data. Participants who had \> 2 consecutive visits that were not evaluable for pain progression were censored at the last evaluable assessment.

    Time frame: Up to Approximately 32 months

  6. Time From Randomization to Disease Progression as Determined by Investigator Assessment After Next-line of Therapy or Death From Any Cause, Whichever Occurs First (PFS2)

    PFS2 was defined as the time from randomization to disease progression as determined by investigator assessment of radiological or clinical progression after next-line of therapy or death from any cause, whichever occurs first.

    Time frame: Up to Approximately 32 months

  7. Prostate-specific Antigen (PSA) Response Rate

    PSA response rate was the percentage of participants who had PSA response defined as a reduction in the PSA level from baseline by \>50%. The reduction in PSA level was confirmed by an additional PSA evaluation performed \>3 weeks from the original response.

    Time frame: Up to Approximately 32 Months

  8. Prostate-specific Antigen (PSA) Undetectable

    PSA undetectable rate was defined as the percentage of participants with detectable PSA (\> 0.2 ng/mL) at baseline, which becomes undetectable (\< 0.2 ng/mL) during study treatment.

    Time frame: Up to Approximately 32 Months

  9. Objective Response Rate (ORR) Per PCWG-Modified RECIST 1.1 as Assessed by BICR

    ORR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on base scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).

    Time frame: Up to Approximately 32 Months

  10. Duration of Response (DOR) Per PCWG- Modified RECIST 1.1 as Assessed by BICR

    DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of a least 5 mm. PD per PCWG was the appearance of \>2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for \>6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to Approximately 32 Months

  11. Number of Participants Who Experience an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Participants who experienced an AE will be reported for each arm.

    Time frame: Up to Approximately 59 Months

  12. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported for each arm.

    Time frame: Up to Approximately 59 Months

07

Results

Posted Nov 18, 2023

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Started626625
Completed00
Not completed626625
Withdrew: Death10289
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject55
Withdrew: Participants ongoing518530

Outcome measures

PrimaryRadiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

rPFS was defined as the time from randomization to occurrence of: radiological tumor progression using RECIST 1.1 as assessed by BICR; progression of bone lesions using PCWG criteria; or death due to any cause. Progression as per modified RECIST 1.1 was ≥20% increase in sum of diameters of target lesions and progression of existing non-target lesions. Progression of bone lesions by PCWG criteria was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and was persistent for ≥6 weeks. The rPFS was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without a rPFS event were censored at the date of last disease assessment.

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.9467 (A one-sided p-value was calculated using the log-rank test stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No) with small strata.) · Hazard ratio (hr): 1.20 · 95% CI 0.96 to 1.49HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No).
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without documented death at the time of the analysis were censored at the date of the last follow-up.

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.85122 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 1.16 · 95% CI 0.88 to 1.53HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)

TFST was defined as the time from randomization to initiation of the first subsequent anti-cancer therapy or death; whichever occurred first. The TFST was calculated using the product limit (Kaplan-Meier) method for censored data. Participants without documented event at time of analysis will be censored at the date of last known time to have not received subsequent new anti-cancer therapy.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)NA (29.0 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.97907 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 1.24 · 95% CI 1.01 to 1.54HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime to First Symptomatic Skeletal-related Event (TTSSRE)

TTSSRE was the time from randomization to the first symptomatic skeletal-related event defined as: use of external-beam radiation therapy (EBRT) to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathologic bone fracture (vertebral or nonvertebral), occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention, whichever occurs first. The TTSSRE was calculated using the Kaplan-Meier method for censored data. Participants without symptomatic skeletal-related events were censored at the last evaluable assessment.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time to First Symptomatic Skeletal-related Event (TTSSRE)
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time to First Symptomatic Skeletal-related Event (TTSSRE)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.27202 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 0.89 · 95% CI 0.61 to 1.30HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was the time from randomization to PSA progression. The PSA progression date was defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. Time to PSA was calculated using Kaplan-Meier method for censored data. Participants without PSA progression were censored at the last PSA date.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time to Prostate-specific Antigen (PSA) ProgressionNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.2972 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 0.92 · 95% CI 0.69 to 1.23HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime to Radiographic Soft Tissue Progression Per Soft Tissue Rules of PCWG-Modified RECIST 1.1 as Assessed by BICR

The time to radiographic soft tissue progression was defined as the time from randomization to radiographic soft tissue progression per soft tissue rules of PCWG-modified RECIST 1.1 as assessed by BICR. Progression was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered progression. Time to radiographic soft tissue progression was calculated using the product-limit (Kaplan-Meier) method for censored data. Participants without radiographic soft tissue progression were censored at the last evaluable assessment.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of PCWG-Modified RECIST 1.1 as Assessed by BICR
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of PCWG-Modified RECIST 1.1 as Assessed by BICRNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.6863 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 1.07 · 95% CI 0.81 to 1.41HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item #3 ("Worst Pain in 24 Hours") and Opiate Use

TTPP was defined as the time from randomization to pain progression as determined by Item 3 of the BPI-SF. Pain progression was defined as: 1) For participants asymptomatic at baseline: a \>2-point change from baseline in the average BPI-SF item 3 score at 2 consecutive visits or initiation of opioid use for pain 2) For participants symptomatic at baseline (average BPI-SF Item 3 score \>0 and/or currently taking opioids; a \>2-point change from baseline in the average BPI-SF Item 3 score and the average worst pain score \>4 and no decrease in average opioid use. TTPP was calculated using the Kaplan-Meier method for censored data. Participants who had \> 2 consecutive visits that were not evaluable for pain progression were censored at the last evaluable assessment.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item #3 ("Worst Pain in 24 Hours") and Opiate Use
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item #3 ("Worst Pain in 24 Hours") and Opiate UseNA (25.4 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.9235 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 1.15 · 95% CI 0.95 to 1.39HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryTime From Randomization to Disease Progression as Determined by Investigator Assessment After Next-line of Therapy or Death From Any Cause, Whichever Occurs First (PFS2)

PFS2 was defined as the time from randomization to disease progression as determined by investigator assessment of radiological or clinical progression after next-line of therapy or death from any cause, whichever occurs first.

Time frame:
Up to Approximately 32 months
Reported as:
Median · Months
Time From Randomization to Disease Progression as Determined by Investigator Assessment After Next-line of Therapy or Death From Any Cause, Whichever Occurs First (PFS2)
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Time From Randomization to Disease Progression as Determined by Investigator Assessment After Next-line of Therapy or Death From Any Cause, Whichever Occurs First (PFS2)NA (29.0 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Log Rank · p = 0.8801 (One-sided p-value based on log-rank test stratified by prior docetaxel for mHSPC (Yes vs No) and presence of high-volume disease (Yes vs No) with small strata.) · Hazard ratio (hr): 1.16 · 95% CI 0.90 to 1.50HR and associated 95% Confidence Interval (CI) were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No).
SecondaryProstate-specific Antigen (PSA) Response Rate

PSA response rate was the percentage of participants who had PSA response defined as a reduction in the PSA level from baseline by \>50%. The reduction in PSA level was confirmed by an additional PSA evaluation performed \>3 weeks from the original response.

Time frame:
Up to Approximately 32 Months
Reported as:
Number · Percentage of participants
Prostate-specific Antigen (PSA) Response Rate
Percentage of participantsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Prostate-specific Antigen (PSA) Response Rate90.3 (87.7 to 92.5)93.0 (90.7 to 94.9)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Miettinen & Nurminen method · p = 0.9576 (One-sided p-value based on Miettinen \& Nurminen method stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No) with small strata.) · Percent difference: -2.7 · 95% CI -5.8 to 0.4Percent difference and associated 95% CI were calculated using Miettinen \& Nurminen method stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No).
SecondaryProstate-specific Antigen (PSA) Undetectable

PSA undetectable rate was defined as the percentage of participants with detectable PSA (\> 0.2 ng/mL) at baseline, which becomes undetectable (\< 0.2 ng/mL) during study treatment.

Time frame:
Up to Approximately 32 Months
Reported as:
Number · Percentage of Participants
Prostate-specific Antigen (PSA) Undetectable
Percentage of ParticipantsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Prostate-specific Antigen (PSA) Undetectable63.4 (59.3 to 67.3)64.1 (60.1 to 68.0)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Miettinen & Nurminen · p = 0.6053 (One-sided p-value based on Miettinen \& Nurminen method stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No) with small strata.) · Percent difference: -0.8 · 95% CI -6.3 to 4.8Percent difference and associated 95% CI were calculated using Miettinen \& Nurminen method stratified by prior docetaxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryObjective Response Rate (ORR) Per PCWG-Modified RECIST 1.1 as Assessed by BICR

ORR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on base scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).

Time frame:
Up to Approximately 32 Months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per PCWG-Modified RECIST 1.1 as Assessed by BICR
Percentage of ParticipantsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Objective Response Rate (ORR) Per PCWG-Modified RECIST 1.1 as Assessed by BICR65.7 (59.5 to 71.6)71.8 (65.8 to 77.4)
Statistical analysis
  • Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT · Miettinen & Nurminen · p = 0.9105 (One-sided p-value based on Miettinen \& Nurminen method stratified prior docataxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No) with small strata.) · Percent difference: -5.6 · 95% CI -13.7 to 2.6Percent difference and associated 95% CI were calculated using Miettinen \& Nurminen method stratified by prior docataxel for mHSPC (Yes/No) and presence of high-volume disease (Yes/No)
SecondaryDuration of Response (DOR) Per PCWG- Modified RECIST 1.1 as Assessed by BICR

DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of a least 5 mm. PD per PCWG was the appearance of \>2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for \>6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to Approximately 32 Months
Reported as:
Median · Months
Duration of Response (DOR) Per PCWG- Modified RECIST 1.1 as Assessed by BICR
MonthsPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Duration of Response (DOR) Per PCWG- Modified RECIST 1.1 as Assessed by BICRNA (22.2 to NA)NA (NA to NA)
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Participants who experienced an AE will be reported for each arm.

Time frame:
Up to Approximately 59 Months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported for each arm.

Time frame:
Up to Approximately 59 Months

Results for this outcome have not been posted.

Adverse events

Collected over Up to Approximately 32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Enzalutamide + ADT105/626 (16.8%)252/625 (40.3%)588/625 (94.1%)
Placebo + Enzalutamide + ADT93/625 (14.9%)145/625 (23.2%)551/625 (88.2%)
Most frequent serious events
Showing 10 of 284
Most frequent serious events
EventPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
Urinary tract infectionInfections and infestations11/6257/625
RashSkin and subcutaneous tissue disorders10/6251/625
Rash maculo-papularSkin and subcutaneous tissue disorders10/6250/625
PneumoniaInfections and infestations9/6257/625
Myocardial infarctionCardiac disorders7/6257/625
ColitisGastrointestinal disorders7/6250/625
PneumonitisRespiratory, thoracic and mediastinal disorders7/6251/625
DeathGeneral disorders6/6252/625
COVID-19Infections and infestations6/6255/625
COVID-19 pneumoniaInfections and infestations4/6256/625
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADT
FatigueGeneral disorders194/625178/625
ArthralgiaMusculoskeletal and connective tissue disorders181/625161/625
RashSkin and subcutaneous tissue disorders148/62558/625
Hot flushVascular disorders110/625144/625
HypertensionVascular disorders108/625130/625
DiarrhoeaGastrointestinal disorders127/62573/625
Back painMusculoskeletal and connective tissue disorders102/625113/625
PruritusSkin and subcutaneous tissue disorders110/62555/625
ConstipationGastrointestinal disorders108/625103/625
NauseaGastrointestinal disorders105/62575/625

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
Mean67.6 ± 8.367.6 ± 8.267.6 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
Female000
Male6266251251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
Hispanic or Latino119112231
Not Hispanic or Latino5055101015
Unknown or Not Reported235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
American Indian or Alaska Native191332
Asian99118217
Native Hawaiian or Other Pacific Islander314
Black or African American171431
White447440887
More than one race393776
Unknown or Not Reported224
Prior Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) at Baseline
Prior Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) at Baseline(Participants)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
Yes6461125
No5625641126
Presence of High-Volume Disease at Baseline
Presence of High-Volume Disease at Baseline(Participants)Pembrolizumab + Enzalutamide + ADTPlacebo + Enzalutamide + ADTTotal
Yes392398790
No234227461
08

Study locations

234 sites
  • Alaska Clinical Research Center ( Site 0274)
    Anchorage, Alaska 99503, United States
  • Providence Alaska Medical Center ( Site 0276)
    Anchorage, Alaska 99508, United States
  • City of Hope Medical Center ( Site 0217)
    Duarte, California 91010, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0241)
    Los Angeles, California 90404, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 0236)
    Aurora, Colorado 80045, United States
  • Hartford HealthCare Medical Group ( Site 0212)
    Manchester, Connecticut 06042, United States
  • Smilow Cancer Center at Yale-New Haven ( Site 0250)
    New Haven, Connecticut 06510, United States
  • Sibley Memorial Hospital ( Site 0275)
    Washington D.C., District of Columbia 20016, United States
  • Winship Cancer Institute of Emory University ( Site 0209)
    Atlanta, Georgia 30322-1013, United States
  • The University of Chicago ( Site 0264)
    Chicago, Illinois 60637, United States
  • Springfield Clinic [Springfield, IL] ( Site 0240)
    Springfield, Illinois 62702, United States
  • Cotton-O'Neil Cancer Center ( Site 0228)
    Topeka, Kansas 66606, United States
  • The Sidney Kimmel Comprehensive Cancer Center ( Site 0204)
    Baltimore, Maryland 21287, United States
  • St. Vincent Frontier Cancer Center-Research ( Site 0213)
    Billings, Montana 59102, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0269)
    Las Vegas, Nevada 89169, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0270)
    New York, New York 10016, United States
  • Weill Cornell Medical College ( Site 0263)
    New York, New York 10065, United States
  • Associated Medical Professionals of NY ( Site 0251)
    Syracuse, New York 13210, United States
  • Duke University ( Site 0206)
    Durham, North Carolina 27710, United States
  • TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0253)
    Cincinnati, Ohio 45212, United States
  • MidLantic Urology ( Site 0273)
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Ralph H. Johnson VA Center ( Site 0256)
    Charleston, South Carolina 29401, United States
  • Carolina Urologic Research Center ( Site 0259)
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates [Nashville, TN] ( Site 0233)
    Nashville, Tennessee 37209, United States
  • Inova Health System ( Site 0205)
    Fairfax, Virginia 22031, United States
  • Urology of Virginia ( Site 0224)
    Virginia Beach, Virginia 23462, United States
  • Fred Hutchinson Cancer Center ( Site 0258)
    Seattle, Washington 98109, United States
  • Chris OBrien Lifehouse ( Site 0300)
    Camperdown, New South Wales 2050, Australia
  • Port Macquarie Base Hospital ( Site 0301)
    Port Macquarie, New South Wales 2444, Australia
  • Riverina Cancer Care Center ( Site 0302)
    Wagga Wagga, New South Wales 2650, Australia
  • Gallipoli Medical Research Ltd ( Site 0309)
    Greenslopes, Queensland 4120, Australia
  • John Flynn Hospital & Medical Centre ( Site 0308)
    Tugun, Queensland 4224, Australia
  • Box Hill Hospital ( Site 0304)
    Box Hill, Victoria 3128, Australia
  • Monash Health ( Site 0305)
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0306)
    Melbourne, Victoria 3000, Australia
  • Fiona Stanley Hospital ( Site 0311)
    Perth, Western Australia 6150, Australia
  • Ordensklinikum Linz GmbH Elisabethinen ( Site 0901)
    Linz, Upper Austria 4020, Austria
  • Landeskrankenhaus Salzburg - Universitatklinikum der PMU ( Site 0900)
    Salzburg, 5020, Austria
  • Krankenhaus der Barmherzigen Brüder Wien ( Site 0904)
    Vienna, 1020, Austria
  • Medizinische Universität Wien ( Site 0903)
    Vienna, 1090, Austria
  • Oncocentro Ceara ( Site 2309)
    Fortaleza, Ceará 60135-237, Brazil
  • Instituto de Cancer e Transplante de Curitiba ICTR ( Site 2306)
    Curitiba, Paraná 80510-130, Brazil
  • Hospital Sao Vicente de Paulo ( Site 2303)
    Passo Fundo, Rio Grande do Sul 99010-080, Brazil
  • Hospital de Clinicas de Porto Alegre ( Site 2304)
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Clinica de Oncologia Reichow ( Site 2308)
    Blumenau, Santa Catarina 89010-340, Brazil
  • Fundacao Dr Amaral Carvalho ( Site 2302)
    Jaú, São Paulo 17210-120, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2305)
    São Paulo, 12460-000, Brazil
  • The Ottawa Hospital ( Site 0100)
    Ottawa, Ontario K1H 8L6, Canada
  • Niagara Health System - St. Catharines ( Site 0107)
    St. Catharines, Ontario L2S 0A9, Canada
  • CISSS de la Monteregie-Centre ( Site 0105)
    Greenfield Park, Quebec J4V 2H1, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0109)
    Montreal, Quebec H2X 3E4, Canada
  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0106)
    Montreal, Quebec H3T 1M5, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0101)
    Québec, Quebec G1J 1Z4, Canada
  • Centro Investigación del Cáncer James Lind ( Site 2401)
    Temuco, Araucania 4800827, Chile
  • IC La Serena Research ( Site 2406)
    La Serena, Coquimbo Region 1720430, Chile
  • Clinica Universidad Catolica del Maule ( Site 2407)
    Talca, Maule Region 3465584, Chile
  • Clinica Alemana ( Site 2408)
    Santiago, Region M. de Santiago 7650568, Chile
  • Pontificia Universidad Catolica de Chile ( Site 2402)
    Santiago, Region M. de Santiago 8330024, Chile
  • Bradfordhill ( Site 2403)
    Santiago, Region M. de Santiago 8420383, Chile
  • Oncocentro ( Site 2400)
    Viña del Mar, Valparaiso 2520598, Chile
  • Peking University First Hospital ( Site 0800)
    Beijing, Beijing Municipality 100034, China
  • Beijing Cancer Hospital ( Site 0802)
    Beijing, Beijing Municipality 100142, China
  • Chongqing Cancer Hospital ( Site 0815)
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated Hospital of Xiamen University ( Site 0816)
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0837)
    Guangdong, Guangdong 510080, China
  • Sun Yat-Sen University Cancer Center ( Site 0825)
    Guangzhou, Guangdong 510060, China
  • Sun Yat Sen Memorial Hospital ( Site 0819)
    Guangzhou, Guangdong 510220, China
  • Southern Medical University Nanfang Hospital ( Site 0838)
    Guangzhou, Guangdong 510515, China
  • Harbin Medical University Cancer Hospital ( Site 0822)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 0818)
    Zhengzhou, Henan 450008, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0829)
    Wuhan, Hubei 430000, China
  • Hubei Cancer Hospital ( Site 0833)
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital ( Site 0817)
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital ( Site 0811)
    Nanjing, Jiangsu 210008, China
  • The First Affiliated Hospital of Nanchang University ( Site 0821)
    Nanchang, Jiangxi 330006, China
  • The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831)
    Xi'an, Shaanxi 710004, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0807)
    Shanghai, Shanghai Municipality 200127, China
  • The first affiliated Hospital of Xi an Jiaotong University ( Site 0812)
    Xi’an, Shanxi 710061, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0804)
    Tianjin, Tianjin Municipality 300000, China
  • 2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0808)
    Hangzhou, Zhejiang 310009, China
  • The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 0830)
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Provincial People's Hospital ( Site 0809)
    Hangzhou, Zhejiang 310014, China
  • Ningbo First Hospital-Urology ( Site 0835)
    Ningbo, Zhejiang 315010, China
  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0834)
    Wenzhou, Zhejiang 325000, China
  • Clinica de la Costa S.A.S. ( Site 2504)
    Barranquilla, Atlántico 080020, Colombia
  • Administradora Country SA - Clinica del Country ( Site 2507)
    Bogotá, Bogota D.C. 110221, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 2506)
    Bogotá, Bogota D.C. 111511, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2509)
    Valledupar, Cesar Department 200001, Colombia
  • Hemato Oncologos ( Site 2503)
    Cali, Valle del Cauca Department 760042, Colombia
  • Rigshospitalet ( Site 1005)
    Copenhagen, Capital Region 2100, Denmark
  • Herlev og Gentofte Hospital. ( Site 1004)
    Herlev, Capital Region 2730, Denmark
  • Aalborg Universitetshospital ( Site 1000)
    Aalborg, North Denmark 9000, Denmark
  • Odense Universitetshospital ( Site 1003)
    Odense, Region Syddanmark 5000, Denmark
  • Vejle Sygehus ( Site 1002)
    Vejle, Region Syddanmark 7100, Denmark
  • Keski-Suomen keskussairaala ( Site 1017)
    Jyväskylä, Central Finland 40620, Finland
  • Tampereen yliopistollinen sairaala ( Site 1022)
    Tampere, Pirkanmaa 33520, Finland
  • HYKS ( Site 1020)
    Helsinki, Southwest Finland 00290, Finland
  • TYKS T-sairaala Syopatautien pkl ( Site 1019)
    Turku, Southwest Finland 20520, Finland
  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1114)
    Strasbourg, Alsace 67200, France
  • Centre Georges Francois Leclerc ( Site 1112)
    Dijon, Cote-d Or 21079, France

Showing the first 100 of 234 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gratzke C, Kwiatkowski M, De Giorgi U, Martins da Trindade K, De Santis M, Armstrong AJ, Niu C, Liu Y, Poehlein CH. KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. Future Oncol. 2023 Jan 27. doi: 10.2217/fon-2022-0776. Online ahead of print. PubMed 36705526 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Oct 2022, 32 months.

Results were first posted in Nov 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2019
First posted
Dec 9, 2019
StartActual
Feb 12, 2020
Primary completionActual
Oct 31, 2022
CompletionActual
Apr 8, 2026
Results first posted
Nov 18, 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The study stopped due to futility
changed Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Completed→Terminated
    Why stopped The study stopped due to futility
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04191096
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Feb 12, 2020
Primary completion
Oct 31, 2022
Completion
Apr 8, 2026
Results posted
Nov 18, 2023
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion